The Non-Malignant Channel is supported with funding from Agios (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHOC 2022 | The management of ITP during and after the COVID-19 pandemic
In this video, Drew Provan, BSc, MBChB, MD, FRCP, FRCPath, Queen Mary University of London, London, UK, shares some insights into how the treatment and management of immune thrombocytopenia (ITP) changed during and after the COVID-19 pandemic. Dr Provan highlights how access to certain agents impacted treatment approaches, and further comments on future aspects to consider in the treatment of ITP. This interview took place at the XIII Eurasian Hematology-Oncology Congress (EHOC) held in Istanbul, Turkey.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
